Novo Nordisk's CEO Has a Comeback Plan

The Journal. by The Wall Street Journal

When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recen...View more